Cargando…

Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers

BACKGROUND: Most studies on immune response after coronavirus disease 2019 (COVID-19) vaccination focused on serum IgG antibodies and cell-mediated immunity, discounting the role of anti-SARS-CoV-2 neutralizing IgA antibodies in preventing viral infection. This study was aimed to quantify serum IgG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salvagno, Gian Luca, Henry, Brandon M., di Piazza, Giovanni, Pighi, Laura, de Nitto, Simone, Bragantini, Damiano, Gianfilippi, Gian Luca, Lippi, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Medical Biochemists of Serbia, Belgrade 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451231/ https://www.ncbi.nlm.nih.gov/pubmed/34616222 http://dx.doi.org/10.5937/jomb0-32373

Ejemplares similares

Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination
por: Lippi, Giuseppe, et al.
Publicado: (2021)

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Variación longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2
por: Lippi, Giuseppe, et al.
Publicado: (2022)

Coronavirus Disease 2019-Related Alterations of Total and Anti-Spike IgG Glycosylation in Relation to Age and Anti-Spike IgG Titer
por: Schwedler, Christian, et al.
Publicado: (2022)

Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
por: Danese, Elisa, et al.
Publicado: (2021)

IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity
por: Wang, Jiong, et al.
Publicado: (2022)

Anti-SARS-CoV-2 spike IgG antibodies prevalence: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2023)

Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG
por: Capetti, Amedeo F., et al.
Publicado: (2021)

The Comparability of Anti-SARS-CoV-2 IgG Levels Measured with Different Immunoassays Varies over Time after Primary BNT162b2 Vaccination and Homologous Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Association of dengue infection with anti-alpha-gal antibodies, IgM, IgG, IgG1, and IgG2
por: Olajiga, Olayinka M., et al.
Publicado: (2022)

Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19
por: Geyer, Chiara E, et al.
Publicado: (2023)

Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy
por: Cosan, Fulya, et al.
Publicado: (2023)

Performance of the Roche/Snibe electrochemiluminescent anti-SARS-COV-2 spike assays compared to the Roche/Abbott IgG nucleocapsid and Abbott IgM spike assays
por: Lau, C.S., et al.
Publicado: (2021)

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
por: Voss, William N., et al.
Publicado: (2021)

Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda
por: Oluka, Gerald Kevin, et al.
Publicado: (2023)

Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients
por: Liao, Baolin, et al.
Publicado: (2021)

Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets
por: Bye, Alexander P., et al.
Publicado: (2021)

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization
por: Izadi, Arman, et al.
Publicado: (2023)

Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy
por: Giossi, Riccardo, et al.
Publicado: (2022)

Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
por: Jeulin, Helene, et al.
Publicado: (2022)

Levels of SARS-COV-2 anti-spike protein receptor-binding domain (S-RBD) IgG in Indonesian-vaccinated healthcare workers: experimental research
por: Tambunan, Betty A., et al.
Publicado: (2023)

Subclasses of allergen-specific IgG: Serum IgG2 and IgG3 levels are not predicted by IgG1/IgG4 levels
por: MacGlashan, Donald, et al.
Publicado: (2021)

IgG response to spike protein of SARS-CoV-2 in healthy individuals and potential of intravenous IgG as treatment for COVID-19
por: Wang, Gang, et al.
Publicado: (2022)

Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies
por: Takahashi, Maika, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India
por: Lone, Kouser Sideeq, et al.
Publicado: (2022)

Disparity between levels of anti-RBD IgG and anti-nucleocapsid protein IgG antibodies in COVID-19–recovered patients who received a kidney transplant
por: Chang, Chih-Chao, et al.
Publicado: (2021)

Screening for IgG4-type anti-nuclear antibodies in IgG4-related disease
por: Kiyama, Kazuhiro, et al.
Publicado: (2015)

Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG
por: Sapkal, Gajanan, et al.
Publicado: (2020)

Evaluación de la prueba Fluorecare de anticuerpos contra la proteína Spike del SARS-CoV-2 en la práctica real
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

A Case of IgG and IgA Anti-Laminin-332 Antibody-Positive Mucous Membrane Pemphigoid with IgG and IgA Anti-Envoplakin and Anti-Periplakin Antibodies
por: Matsushima, Yoshiaki, et al.
Publicado: (2022)

Variant-dependent oxidative and cytokine responses of human neutrophils to SARS-CoV-2 spike protein and anti-spike IgG1 antibodies
por: Almeida, Nathalie Bonatti Franco, et al.
Publicado: (2023)

Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months
por: Serwanga, Jennifer, et al.
Publicado: (2023)

A Serological Analysis of the Humoral Immune Responses of Anti-RBD IgG, Anti-S1 IgG, and Anti-S2 IgG Levels Correlated to Anti-N IgG Positivity and Negativity in Sicilian Healthcare Workers (HCWs) with Third Doses of the mRNA-Based SARS-CoV-2 Vaccine: A Retrospective Cohort Study
por: Serra, Nicola, et al.
Publicado: (2023)

Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

Evaluation of Covid-19 anti-spike IgG antibody five months after the second Covid-19 vaccination
por: Rafie, Reyhaneh Alipoor, et al.
Publicado: (2023)

Determination of IgG1 and IgG3 SARS-CoV-2 Spike Protein and Nucleocapsid Binding—Who Is Binding Who and Why?
por: Iles, Jason K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fcu8qp0foft5ddk43giav7t1ld